Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Development
Blackstone Life Sciences has entered into an agreement to provide Pfizer with up to $1.5 billion in funding to support the development of berobenatide, a potential first-in-class monthly GLP-1 receptor agonist designed for weight loss. This strategic financing aims to offset the significant research and development costs associated with advancing this new obesity treatment. The deal is structured around milestone-based payments, meaning Blackstone's capital infusion will be contingent upon regulatory approvals and subsequent sales performance. This partnership highlights the intense competition in the metabolic health market as pharmaceutical companies seek more convenient dosing schedules for weight management medications.
Topics: Drug Development GLP-1 Pharmaceuticals Weight Loss Drugs
Read the full article at Seeking Alpha
Part of the story Blackstone to provide Pfizer up to $1.5B to advance monthly GLP-1 for weight loss (3 articles)